CN101534858A - 预防和治疗癌症转移和癌症转移相关性骨丢失的方法 - Google Patents

预防和治疗癌症转移和癌症转移相关性骨丢失的方法 Download PDF

Info

Publication number
CN101534858A
CN101534858A CNA2007800067993A CN200780006799A CN101534858A CN 101534858 A CN101534858 A CN 101534858A CN A2007800067993 A CNA2007800067993 A CN A2007800067993A CN 200780006799 A CN200780006799 A CN 200780006799A CN 101534858 A CN101534858 A CN 101534858A
Authority
CN
China
Prior art keywords
antibody
csf
antibodies
amino acid
transition period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800067993A
Other languages
English (en)
Chinese (zh)
Inventor
M·卡瓦诺
C·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Xoma Technology Ltd USA
Original Assignee
Novartis Vaccines and Diagnostics Inc
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Xoma Technology Ltd USA filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN101534858A publication Critical patent/CN101534858A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800067993A 2006-01-05 2007-01-04 预防和治疗癌症转移和癌症转移相关性骨丢失的方法 Pending CN101534858A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75694406P 2006-01-05 2006-01-05
US60/756,944 2006-01-05

Publications (1)

Publication Number Publication Date
CN101534858A true CN101534858A (zh) 2009-09-16

Family

ID=38219019

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800067993A Pending CN101534858A (zh) 2006-01-05 2007-01-04 预防和治疗癌症转移和癌症转移相关性骨丢失的方法

Country Status (12)

Country Link
US (1) US20090246208A1 (https=)
EP (2) EP2705854A1 (https=)
JP (2) JP5580535B2 (https=)
KR (1) KR20080083187A (https=)
CN (1) CN101534858A (https=)
AU (1) AU2007205048B2 (https=)
BR (1) BRPI0706314A2 (https=)
CA (1) CA2636149A1 (https=)
IL (1) IL192568A0 (https=)
RU (1) RU2470665C2 (https=)
TW (1) TW200738262A (https=)
WO (1) WO2007081879A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324491A (zh) * 2013-03-15 2016-02-10 生物医学研究机构基金会 用于癌症转移的诊断和治疗的方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
CN102918061B (zh) * 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
JP2014520873A (ja) 2011-07-18 2014-08-25 ザ ユニバーシティ オブ メルボルン ｃ−Ｆｍｓアンタゴニストの使用
WO2013033206A2 (en) * 2011-08-29 2013-03-07 University Of Rochester Compositions and methods for inhibiting ccl3
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN103044555B (zh) * 2012-07-05 2016-08-31 雷克塞德（苏州）生物医药有限公司 包含cFms胞外片段的融合蛋白质及其制备方法和应用
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
SG11201507871XA (en) 2013-04-12 2015-10-29 Morphosys Ag Antibodies targeting m-csf
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RU2551622C1 (ru) * 2014-02-20 2015-05-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения опухолей позвоночника
AU2015280362B2 (en) 2014-06-23 2021-03-04 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
RU2609871C1 (ru) * 2015-08-10 2017-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Противоопухолевое средство
RU2631486C1 (ru) * 2016-06-17 2017-09-22 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната
CN109790220A (zh) 2016-08-25 2019-05-21 豪夫迈·罗氏有限公司 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
DK0457804T3 (da) * 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6025146A (en) * 1995-06-05 2000-02-15 Chiron Corporation Identification of M-CSF agonists and antagonists
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
RU2153358C1 (ru) * 1999-11-10 2000-07-27 Центральный научно-исследовательский рентгенорадиологический институт МЗ России Способ лечения остеолитических метастазов
US20030199531A1 (en) 2001-07-19 2003-10-23 Todd Wipke YIGSR peptidomimetics and methods for using the same
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
RS52966B (sr) * 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
DK2311873T3 (en) * 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
BRPI0710548B8 (pt) * 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324491A (zh) * 2013-03-15 2016-02-10 生物医学研究机构基金会 用于癌症转移的诊断和治疗的方法
CN105324491B (zh) * 2013-03-15 2021-10-26 生物医学研究机构基金会 用于癌症转移的诊断和治疗的方法

Also Published As

Publication number Publication date
CA2636149A1 (en) 2007-07-19
JP5580535B2 (ja) 2014-08-27
TW200738262A (en) 2007-10-16
JP2012229271A (ja) 2012-11-22
AU2007205048A1 (en) 2007-07-19
WO2007081879A2 (en) 2007-07-19
IL192568A0 (en) 2011-08-01
RU2008132150A (ru) 2010-02-10
EP1984024A2 (en) 2008-10-29
JP2009522369A (ja) 2009-06-11
RU2470665C2 (ru) 2012-12-27
EP2705854A1 (en) 2014-03-12
KR20080083187A (ko) 2008-09-16
AU2007205048B2 (en) 2013-07-04
WO2007081879A3 (en) 2007-09-07
US20090246208A1 (en) 2009-10-01
BRPI0706314A2 (pt) 2011-03-22

Similar Documents

Publication Publication Date Title
JP5580535B2 (ja) 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
ES2689328T3 (es) Anticuerpo monoclonal M-CSF-específico y usos del mismo
JP2021526847A (ja) 抗ｇｄｆ１５抗体、組成物および使用の方法
KR20190098255A (ko) 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
JP2015013900A (ja) Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
CN107530419A (zh) 治疗疾病的组合疗法
KR20170052666A (ko) 진행성 골화성 섬유이형성증의 치료
CA2451955A1 (en) Antibodies to opgl
KR20180037984A (ko) 개선된 결합 특징, 기능적 특징 및 안전성 특징을 구비한 항-cd154 항체 및 인간 면역요법에서의 용도
KR20200143718A (ko) 이식편 거부반응 예방에 사용하기 위한 항-cd40 항체
JP2020532991A (ja) プログラム細胞死タンパク質１に対する抗体
KR20220007086A (ko) T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
US20220227876A1 (en) Rank antagonists and uses thereof
KR101691534B1 (ko) 류마티스 관절염 및 골다공증 치료용 ｉｌ-20 길항제의 용도
JP2025172885A (ja) 腫瘍治療のための二重特異性融合タンパク質
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
HK1195254A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
MX2008008570A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
JP2016516746A (ja) 溶骨性骨障害を治療するための組成物及び方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090916